FDA’s ‘Accelerated Approvals’ Are Critical But Raise Thorny Issues

類似資料

• FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
  著者:: Muhammad Mazhar Azam, 等
  出版事項: (2024-12-01)
• Flexibility and innovation in the FDA’s novel regulatory approval strategies for hematologic drugs
  著者:: Farrell, Ann T., 等
  出版事項: (2017)
• FDA’s commitment to transparency
  著者:: Guharoy, Roy, 等
  出版事項: (2021)
• The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
  著者:: Marks, Peter
  出版事項: (2019)
• Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
  著者:: Kesselheim, Aaron S., 等
  出版事項: (2016)